Stem cell infusion for low blood counts after CAR-T therapy
Part of Blood & lymphatic clinical trials.
This trial tests if giving back your own stored stem cells can help restore low blood cell counts that persist or develop 30 to 90 days after CAR-T therapy for multiple myeloma.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older.
- You must have multiple myeloma.
- You have had CAR-T therapy and your disease is in remission or not needing immediate treatment.
- You have low blood counts (neutrophils, platelets, or hemoglobin) that started or continue between 30 and 90 days after CAR-T infusion.
- You must have at least 1 million stored stem cells per kilogram of body weight available for infusion.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if umbilical cord stem cells can help restore low blood counts in people with leukemia, lymphoma, or myeloma who still have low blood cell levels three weeks after CAR-T therapy. It aims to improve recovery and reduce infection or bleeding risks.
This study tests whether umbilical cord blood cells can help people whose blood counts stay dangerously low after immune-based cancer treatments like CAR-T or bispecific antibodies. The treatment aims to boost your blood cell recovery and reduce the need for transfusions.
This study combines a stem cell transplant with a special immune therapy (CAR-T) to treat multiple myeloma that is very aggressive and has not responded well to initial treatments. The goal is to see if this combination can better control the cancer.
This trial tests whether CAR-T cells, a type of immunotherapy that targets specific markers on cancer cells, can treat blood cancers that have come back or not responded to standard treatment. It may offer a new option for people with lymphoma, leukemia, or multiple myeloma.
This trial tests giving patients their own stored stem cells after CAR-T therapy to help recover low blood counts. It is for people with B-cell non-Hodgkin lymphoma whose blood counts are still low after CAR-T and who have a stable response to treatment.
This trial tests a new treatment that combines a stem cell transplant with special immune cells (called CAR-T cells) to fight multiple myeloma. The goal is to see if this combined approach helps people with newly diagnosed myeloma achieve better control of their disease.
Hear when a new Prolonged Cytopenia Following CAR-T Therapy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.